Vertex Pharmaceuticals (NASDAQ:VRTX) announced Friday a reimbursement agreement with England’s National Health Service (NHS) ...

The epigenetic state of chromatin, gene activity, and chromosomal positions are interrelated. A research team from the IPK ...

It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.

Around 1,700 people could be eligible for the one-time treatment, which is seen as a less risky alternative to a donor stem ...

The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

RFK Jr.'s comments about the gene-editing technology raise a question about how he would regulate it as head of HHS.

Australian researchers have successfully introduced an improved version of Cas12a gene-editing enzyme in mice.

Once a week, Sun Kai has a video call with his mother, and they discuss his day-to-day life. But Sun’s mother died five years ...

Britain's National Health Service (NHS) will provide a cutting-edge gene therapy that aims to cure sickle cell disease, the ...

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...

Morgan Stanley lowered the firm’s price target on Crispr Therapeutics (CRSP) to $30 from $45 and keeps an Underweight rating on the shares. The ...

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $41.21, denoting a -1.44% change from the preceding trading day. ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE ...